Both the classical mIL-6R-mediated signaling pathway and the sIL-6R-mediated IL-6 trans-signaling pathway lead to the activation of the JAK/STAT signaling pathway, a major therapeutic target for immunological diseases including rheumatoid arthritis [38,39]. The gene discussed is IL6R; the disease is rheumatoid arthritis.